Gene therapy could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy
A new study in mice shows that replacement of a dysfunctional gene could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disorder in which the muscular walls of the heart progressively weaken and put patients at risk of dangerous irregular heartbeats.
Source: news-medical.net
